Top-News

RADIUS HEALTH News

Keine aktuellen Kursdaten verfügbar
ISIN: US7504691087
Typ: Aktie

RADIUS HEALTH News

23.06.22 - PR Newswire
Menarini Group und Radius Health reichen bei der U.S. FDA einen Antrag auf ein neues Medikament für Elacestrant ein
Menarini Group und Radius Health reichen bei der U.S. FDA einen Antrag auf ein neues Medikament für Elacestrant ein PR Newswire
23.06.22 - PR Newswire
Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient Square
Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient Square PR Newswire
22.06.22 - PR Newswire
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant PR Newswire
22.06.22 - PR Newswire
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant PR Newswire
08.06.22 - PR Newswire
Menarini Group und Radius Health, Inc. präsentieren auf der Jahrestagung 2022 der American Society of Clinical Oncology (ASCO) eine Subgruppenanalyse der zulassungsrelevanten Phase-III-Studie EMERALD mit Elacestrant
Menarini Group und Radius Health, Inc. präsentieren auf der Jahrestagung 2022 der American Society of Clinical Oncology (ASCO) eine Subgruppenanalyse der ...
06.06.22 - PR Newswire
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology ...
06.06.22 - PR Newswire
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology ...
23.05.22 - PR Newswire
Thinking about buying stock in Radius Health, Humanigen, GoldMining, Porch Group, or BigBear.ai?
Thinking about buying stock in Radius Health, Humanigen, GoldMining, Porch Group, or BigBear.ai? PR Newswire
23.05.22 - PR Newswire
Menarini Group und Radius Health, Inc. geben die Veröffentlichung der Daten der zulassungsrelevanten klinischen Phase-III-Studie EMERALD im Journal of Clinical Oncology bekannt
Menarini Group und Radius Health, Inc. geben die Veröffentlichung der Daten der zulassungsrelevanten klinischen Phase-​III-Studie EMERALD im Journal of Clinical Oncology ...
20.05.22 - PR Newswire
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology PR Newswire
20.05.22 - PR Newswire
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology PR Newswire
20.10.21 - PR Newswire
Thinking about buying stock in Vinco Ventures, Radius Health, FuelCell Energy, BlackBerry, or Peabody Energy?
Thinking about buying stock in Vinco Ventures, Radius Health, FuelCell Energy, BlackBerry, or Peabody Energy? PR Newswire
05.01.21 - PR Newswire
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada PR Newswire
05.01.21 - PR Newswire
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada PR Newswire
27.09.20 - PR Newswire
Radius Health & Menarini-Gruppe liefern Elacestrant Update
Radius Health & Menarini-​Gruppe liefern Elacestrant Update PR Newswire
25.09.20 - PR Newswire
Radius Health & Menarini Group Provide Elacestrant Update
Radius Health & Menarini Group Provide Elacestrant Update PR Newswire
25.09.20 - PR Newswire
Radius Health & Menarini Group Provide Elacestrant Update
Radius Health & Menarini Group Provide Elacestrant Update Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with ...
15.08.16 - PR Newswire
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you choose
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-​trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you ...

Newssuche

Videos

newspaper
26.04.24 +6,31%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »